Document is current
Any future updates will be listed below
-
Authors
Barnett, Daniel https://orcid.org/0000-0002-1340-4413
Zimmer, Till S.
Booraem, Caroline https://orcid.org/0009-0000-3294-6253
Palaguachi, Fernando
Meadows, Samantha M.
Xiao, Haopeng https://orcid.org/0000-0002-4166-647X
Wong, Man Ying
Luo, Wenjie
Gan, Li
Chouchani, Edward T. https://orcid.org/0000-0002-9776-8790
Orr, Anna G. https://orcid.org/0000-0002-4036-4277
Orr, Adam L. https://orcid.org/0000-0003-0338-7709
-
Funding
Funding for this research was provided by:
Foundation for the National Institutes of Health (F31AG084165)
Foundation for the National Institutes of Health (K99AG073461)
Foundation for the National Institutes of Health (R01AG064239)
Foundation for the National Institutes of Health (DK123095 and AG071966)
Foundation for the National Institutes of Health (R01AG068091)
BrightFocus Foundation (BFA2023008F)
BrightFocus Foundation (A2019363S)
Alzheimer's Association (23AARF-1029892)
Alzheimer's Association (AARG-17-533273)
American Federation for Aging Research (NA)
- License Information
-
More Information
Article History
Received: 7 August 2024
Accepted: 9 September 2025
First Online: 4 November 2025
Competing interests
: A.L.O. and A.G.O. have a patent application WO20221333237A2 for the use of SELs in treating neurodegenerative disorders and STAT3-linked cancers. E.T.C. is co-founder and equity holder of Matchpoint Therapeutics and Aevum Therapeutics. The other authors declare no competing interests.
